Loading organizations...
Based in Madrid, Spain, Corify Care develops non-invasive cardiac mapping technology designed to visualize the heart's electrical activity in real-time and improve the clinical diagnosis and treatment of arrhythmias. The company's flagship ACORYS system utilizes body surface potentials and three-dimensional torso models to generate detailed electroanatomical maps in under ten minutes without requiring traditional CT or MRI scans. Operating with a team of one to ten employees, the medical device startup recently secured a €6 million funding round in December 2024, comprising €3 million in private equity and €3 million in public grants. This capital injection, backed by lead investors Clave Capital, CDTI, and Genesis Biomed, will support the commercial expansion of its CE-marked system across European and United States hospital markets. Corify Care was founded in 2019 by Andreu Climent, María Guillem, and Felipe Atienza.
Corify Care has raised $4.0M across 2 funding rounds.
Corify Care has raised $4.0M in total across 2 funding rounds.
Corify Care has raised $4.0M in total across 2 funding rounds.
Corify Care's investors include Clave Capital.
Corify Care has raised $4.0M across 2 funding rounds. Most recently, it raised $3.0M Series U in December 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2024 | $3M Series U | — | Clave Capital | Announced |
| Jul 1, 2021 | $1M Seed | — | Clave Capital | Announced |
Corify Care is a biomedical technology company developing ACORYS, a non-invasive, AI-powered cardiac mapping system that creates real-time, beat-to-beat electroanatomic maps of the entire heart in under 10 minutes using 128 body-surface sensors.[1][2][5] It serves clinicians treating patients with cardiac arrhythmias, particularly atrial fibrillation (AFib) affecting over 30 million worldwide, by enabling precise diagnosis, personalized ablation guidance, and reduced procedure risks, times, and costs—addressing failures in over 50-60% of complex cases.[2][3][4] Growth momentum includes €6M in recent funding for European scaling, CE Mark under MDR in July 2024, over 1,000 patients in clinical trials, Mayo Clinic collaboration (May 2025), and pending FDA approval for U.S. entry.[3][4]
Founded in 2019 as a spin-off from Universitat Politècnica de València, Corify Care originated from research at Hospital Universitario Gregorio Marañón in Madrid and the university, combining high-density hardware with AI algorithms for arrhythmia mapping.[1][2] Key founders include biomedical engineers Andreu Climent (current CEO) and María Guillem, alongside renowned cardiologists Felipe Atienza and Francisco Fernández-Avilés.[2] Early traction came from EIT Health support, winning the EIT Innovation Award in 2020, preliminary validation with 150+ patients in Spain and the U.S., and the €2.5M SAVE-COR project funding clinical trials across Spain and Portugal.[1][2][4] These milestones propelled regulatory progress and market readiness.
Corify Care rides the wave of AI in precision cardiology, targeting the exploding AFib epidemic—10.7M patients in Europe now, projected to 2% of population by 2050 amid aging demographics and rising cardiovascular disease.[2][4] Timing aligns with regulatory shifts like Europe's MDR and U.S. FDA pathways, plus post-pandemic demand for non-invasive, efficient diagnostics amid €13.5B+ annual waste from failed ablations.[2][4] Market tailwinds include EIT Health's innovation ecosystem and clinician adoption needs for complex cases (50%+ failure rates).[3][4] It influences the field by pioneering "imageless ECGI," enabling outpatient mapping, reducing invasiveness, and setting standards for AI-personalized cardiac interventions, potentially saving millions of lives globally.[1][3]
Corify Care is poised for explosive growth with U.S. FDA clearance imminent, €6M fueling ACORYS deployment across Europe, and Mayo Clinic enhancing clinical integration—positioning it as a global leader in arrhythmia care.[3][4] Trends like AI-digital twins, expanded indications (e.g., pacemakers), and value-based healthcare will accelerate adoption, especially as AFib burdens healthcare systems. Its influence may evolve from disruptor to standard-of-care provider, revolutionizing treatments for 60M+ patients and exemplifying university spin-offs' impact, much like its origins promised: quick, accurate, safe cardiac mapping to save hearts.[1][5]
